225 related articles for article (PubMed ID: 17387005)
1. Formulation development and manufacturing of a gastrin/CCK-2 receptor targeting peptide as an intermediate drug product for a clinical imaging study.
Sosabowski JK; Lee M; Dekker BA; Simmons BP; Singh S; Beresford H; Hagan SA; McKenzie AJ; Mather SJ; Watson SA
Eur J Pharm Sci; 2007 Jun; 31(2):102-11. PubMed ID: 17387005
[TBL] [Abstract][Full Text] [Related]
2. Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential.
Behr TM; Béhé M; Angerstein C; Gratz S; Mach R; Hagemann L; Jenner N; Stiehler M; Frank-Raue K; Raue F; Becker W
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3124s-3138s. PubMed ID: 10541353
[TBL] [Abstract][Full Text] [Related]
3. Cyclic minigastrin analogues for gastrin receptor scintigraphy with technetium-99m: preclinical evaluation.
von Guggenberg E; Sallegger W; Helbok A; Ocak M; King R; Mather SJ; Decristoforo C
J Med Chem; 2009 Aug; 52(15):4786-93. PubMed ID: 19591486
[TBL] [Abstract][Full Text] [Related]
4. Gastrin and cholecystokinin peptide-based radiopharmaceuticals: an in vivo and in vitro comparison.
Tornesello AL; Aurilio M; Accardo A; Tarallo L; Barbieri A; Arra C; Tesauro D; Morelli G; Aloj L
J Pept Sci; 2011 May; 17(5):405-12. PubMed ID: 21351319
[TBL] [Abstract][Full Text] [Related]
5. Methoxinine - an alternative stable amino acid substitute for oxidation-sensitive methionine in radiolabelled peptide conjugates.
Grob NM; Behe M; von Guggenberg E; Schibli R; Mindt TL
J Pept Sci; 2017 Jan; 23(1):38-44. PubMed ID: 28054429
[TBL] [Abstract][Full Text] [Related]
6. From preclinical development to clinical application: Kit formulation for radiolabelling the minigastrin analogue CP04 with In-111 for a first-in-human clinical trial.
Pawlak D; Rangger C; Kolenc Peitl P; Garnuszek P; Maurin M; Ihli L; Kroselj M; Maina T; Maecke H; Erba P; Kremser L; Hubalewska-Dydejczyk A; Mikołajczak R; Decristoforo C
Eur J Pharm Sci; 2016 Mar; 85():1-9. PubMed ID: 26826279
[TBL] [Abstract][Full Text] [Related]
7. A kit formulated under good manufacturing practices for labeling human epidermal growth factor with 111In for radiotherapeutic applications.
Reilly RM; Scollard DA; Wang J; Mondal H; Chen P; Henderson LA; Bowen BM; Vallis KA
J Nucl Med; 2004 Apr; 45(4):701-8. PubMed ID: 15073268
[TBL] [Abstract][Full Text] [Related]
8. Targeting of CCK-2 receptor-expressing tumors using a radiolabeled divalent gastrin peptide.
Sosabowski JK; Matzow T; Foster JM; Finucane C; Ellison D; Watson SA; Mather SJ
J Nucl Med; 2009 Dec; 50(12):2082-9. PubMed ID: 19910426
[TBL] [Abstract][Full Text] [Related]
9. Biodistribution and elimination characteristics of two 111In-labeled CCK-2/gastrin receptor-specific peptides in rats.
Trejtnar F; Laznicek M; Laznickova A; Kopecky M; Petrik M; Béhé M; Schmidt J; Maecke H; Maina T; Nock B
Anticancer Res; 2007; 27(2):907-12. PubMed ID: 17465219
[TBL] [Abstract][Full Text] [Related]
10. Targeting of cholecystokinin B/gastrin receptor in colonic, pancreatic and hepatocellular carcinoma cell lines.
Savage K; Waller HA; Stubbs M; Khan K; Watson SA; Clarke PA; Grimes S; Michaeli D; Dhillon AP; Caplin ME
Int J Oncol; 2006 Dec; 29(6):1429-35. PubMed ID: 17088981
[TBL] [Abstract][Full Text] [Related]
11. Optimised labeling, preclinical and initial clinical aspects of CCK-2 receptor-targeting with 3 radiolabeled peptides.
Breeman WA; Fröberg AC; de Blois E; van Gameren A; Melis M; de Jong M; Maina T; Nock BA; Erion JL; Mäcke HR; Krenning EP
Nucl Med Biol; 2008 Nov; 35(8):839-49. PubMed ID: 19026945
[TBL] [Abstract][Full Text] [Related]
12. Formulation development and stability testing of oral morphine solution utilizing preformulation approach.
Preechagoon D; Sumyai V; Tontisirin K; Aumpon S; Pongjanyakul T
J Pharm Pharm Sci; 2005 Aug; 8(2):362-9. PubMed ID: 16124948
[TBL] [Abstract][Full Text] [Related]
13. Targeting of a CCK(2) receptor splice variant with (111)In-labelled cholecystokinin-8 (CCK8) and (111)In-labelled minigastrin.
Laverman P; Roosenburg S; Gotthardt M; Park J; Oyen WJ; de Jong M; Hellmich MR; Rutjes FP; van Delft FL; Boerman OC
Eur J Nucl Med Mol Imaging; 2008 Feb; 35(2):386-92. PubMed ID: 17934729
[TBL] [Abstract][Full Text] [Related]
14. The impact of primary packaging on the quality of parenteral products.
Solomun L; Ibric S; Boltic Z; Djuric Z; Stupar B
J Pharm Biomed Anal; 2008 Nov; 48(3):744-8. PubMed ID: 18786797
[TBL] [Abstract][Full Text] [Related]
15. Novel indium-111 labeled gastrin peptide analogues (MG-CL1-4): synthesis and quality control.
Naqvi SA; Khan ZA; Nagra SA; Yar M; Sherazi TA; Shahzad SS; Shah SQ; Mahmood N; Ishfaq MM; Mather SJ
Pak J Pharm Sci; 2013 Mar; 26(2):299-305. PubMed ID: 23455200
[TBL] [Abstract][Full Text] [Related]
16. Stability of bortezomib 1-mg/mL solution in plastic syringe and glass vial.
André P; Cisternino S; Chiadmi F; Toledano A; Schlatter J; Fain O; Fontan JE
Ann Pharmacother; 2005 Sep; 39(9):1462-6. PubMed ID: 15985470
[TBL] [Abstract][Full Text] [Related]
17. Stability studies of anticancer agent bis(4-fluorobenzyl)trisulfide and synthesis of related substances.
Bao Y; Mo X; Xu X; He Y; Xu X; An H
J Pharm Biomed Anal; 2008 Nov; 48(3):664-71. PubMed ID: 18678459
[TBL] [Abstract][Full Text] [Related]
18. Preclinical evaluation of gastrin derivatives labelled with 111In: radiolabelling, affinity profile and pharmacokinetics in rats.
Melicharova L; Laznickova A; Laznicek M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2014 Dec; 158(4):544-51. PubMed ID: 24108197
[TBL] [Abstract][Full Text] [Related]
19. Formulation development of frozen parenteral dosage forms.
Chilamkurti RN
J Parenter Sci Technol; 1992; 46(4):124-9. PubMed ID: 1453281
[TBL] [Abstract][Full Text] [Related]
20. Stability of doripenem in vitro in representative infusion solutions and infusion bags.
Psathas PA; Kuzmission A; Ikeda K; Yasuo S
Clin Ther; 2008 Nov; 30(11):2075-87. PubMed ID: 19108795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
